Disease dilemma: Eliminate eczema

There's been good news lately for sufferers of eczema, the itchy andoften painful inflammatory skin disease that affects more than 15 millionAmericans. Until recently, only steroids could normalize skin. But a nonsteroidalprescription drug called Protopic is now available.

Related Videos
Related Content

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022
© 2023 MJH Life Sciences

All rights reserved.